Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2018-04-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-018-6786-xPMID 29679303
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Effects and the Mechanisms of Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

  2020cited by this paper
• Canagliflozin and cardiovascular and renal events in type 2 diabetes

  2018cited by this paper
• EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY

  2018cited by this paper
• Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

  2017cited by this paper
• Novel Diabetes Drugs and the Cardiovascular Specialist.

  2017influential reference
• Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

  2017cited by this paper
• Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action

  2017cited by this paper
• Standards of Medical Care in Diabetes—2017 Abridged for Primary Care Providers

  2017cited by this paper
• Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials

  2017cited by this paper
• How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

  2017cited by this paper
• SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System.

  2017cited by this paper
• Management of Type 2 Diabetes in 2017: Getting to Goal.

  2017cited by this paper
• Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation

  2017cited by this paper
• Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure

  2017cited by this paper
• Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

  2017cited by this paper
• Strategies for Diabetes Management: Using Newer Oral Combination Therapies Early in the Disease

  2016cited by this paper
• The Sphingosine 1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?

  2016cited by this paper
• New Oral Hypoglycemic Agents and Cardiovascular Risk. Crossing the Metabolic Border.

  2016cited by this paper
• Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  2016influential reference
• Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

  2016cited by this paper
• Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

  2016cited by this paper
• CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

  2016cited by this paper
• Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK

  2016cited by this paper
• Sodium-glucose cotransporter 2 inhibition: cardioprotection by treating diabetes-a translational viewpoint explaining its potential salutary effects.

  2016cited by this paper
• Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion

  2016cited by this paper
• Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica

  2016cited by this paper
• 8. Pharmacologic Approaches to Glycemic Treatment

  2016cited by this paper
• Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

  2016cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes

  2015cited by this paper
• SGLT2 Inhibitors: The Latest “New Kids on the Block”!

  2015cited by this paper
• Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  2015cited by this paper
• HDL Dysfunction: Is the Answer in the Sphinx's Riddle?

  2015cited by this paper
• HDL: Quality or quantity?

  2015cited by this paper
• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

  2015cited by this paper
• Role of HDL in Those with Diabetes

  2014cited by this paper
• Role of HDL in those with diabetes.

  2014cited by this paper
• Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

  2014cited by this paper
• Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.

  2014cited by this paper
• Pathophysiology of Acute Coronary Syndrome

  2014cited by this paper
• Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study).

  2014cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Beginning to understand high-density lipoproteins.

  2014cited by this paper
• Efficacy and safety of dipeptidyl peptidase‐4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta‐analysis

  2014cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

  2013cited by this paper
• Metformin: an old but still the best treatment for type 2 diabetes

  2013influential reference
• Action to Control Cardiovascular Risk in Diabetes

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes

  2012cited by this paper
• Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and its Association with Complications in Patients with type 2 Diabetes Mellitus

  2012cited by this paper
• SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects

  2012cited by this paper
• Basal insulin and cardiovascular and other outcomes in dysglycemia.

  2012cited by this paper
• Experimental Models for the Investigation of High-Density Lipoprotein–Mediated Cholesterol Efflux

  2011cited by this paper
• Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

  2010cited by this paper
• Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?

  2010cited by this paper
• [Importance of HDL cholesterol in atherothrombosis: how did we get here? Where are we going?].

  2010cited by this paper
• Effects of Intensive Glucose Lowering in Type 2 Diabetes

  2009cited by this paper
• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

  2009cited by this paper
• Effects of intensive glucose lowering in type 2 diabetes.

  2008cited by this paper
• Long-term follow-up after tight control of blood pressure in type 2 diabetes.

  2008cited by this paper
• Neurological Disorders: Public Health Challenges

  2007cited by this paper
• Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells.

  2007cited by this paper
• Projections of Global Mortality and Burden of Disease from 2002 to 2030

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study.

  2003cited by this paper
• The management of type 2 diabetes.

  2003cited by this paper
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

  2000cited by this paper
• Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Insulin, ketone bodies, and mitochondrial energy transduction

  1995cited by this paper

• Meta-analysis of the efficacy and safety of SGLT-2 inhibitors in patients with heart failure and type 2 diabetes mellitus

  2025cites this paper
• Impact of Empagliflozin Versus Dapagliflozin on Left Ventricular Remodeling in Heart Failure Patients: A 1‐Year Comparative Study

  2025cites this paper
• Evaluating the Safety and Efficacy of SGLT-2 Inhibitors on Reducing Cardiovascular and Renal Mortality, Morbidity and Inflammatory Outcomes in Various Patient Populations: A Systematic Review and Meta-Analysis of 92 920 Patients

  2025cites this paper
• Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN‐HF study

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Aortic stenosis: a review on acquired pathogenesis and ominous combination with diabetes mellitus

  2023cites this paper
• Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control

  2023cites this paper
• Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism

  2022cites this paper
• PHARMACOKINETIC INVESTIGATION OF REMOGLIFLOZIN IN RAT PLASMA SAMPLES BY HIGH-THROUGHPUT HPLC-MS-MS

  2022cites this paper
• The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

  2022cites this paper
• Diabetes Mellitus and Its Implications in Aortic Stenosis Patients

  2021cites this paper
• Gliflozinas: más que antidiabéticos orales. Una breve revisión de la literatura

  2021cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure.

  2021cites this paper
• Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence

  2021cites this paper
• Cardiorenal effects of newer antidiabetic agents

  2020cites this paper
• Dapagliflozin Inhibits Cell Adhesion to Collagen I and IV and Increases Ectodomain Proteolytic Cleavage of DDR1 by Increasing ADAM10 Activity

  2020cites this paper
• Survival benefit of revascularization versus optimal medical therapy alone for chronic total occlusion management in patients with diabetes

  2020cites this paper
• Effects of Sodium–Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction

  2020cites this paper
• Pharmacokinetic/Pharmacodynamic Properties and Clinical Use of SGLT2 Inhibitors in Non-Asian and Asian Patients with Type 2 Diabetes and Chronic Kidney Disease

  2020cites this paper
• Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.

  2020cites this paper
• Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

  2020cites this paper
• The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction

  2020cites this paper
• Canagliflozin Extends Lifespan in Genetically Heterogeneous Male But Not Female Mice

  2020cites this paper
• PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.

  2020cites this paper
• Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy

  2020cites this paper
• Canagliflozin extends life span in genetically heterogeneous male but not female mice

  2020cites this paper
• Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.

  2020cites this paper
• Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction.

  2020cites this paper
• University of Groningen Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction Yurista,

  2020cites this paper
• Canagliflozin To Slow Renal Insufficiency Progression in Non-Diabetic Chronic Kidney Disease

  2020cites this paper
• SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

  2019cites this paper
• Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the “Cardiac Benefits” of Empagliflozin Independent of its Hypoglycemic Activity?

  2019cites this paper
• Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

  2019cites this paper
• SGLT Receptors and Myocardial Ischemia-Reperfusion Injury: Inhibition of SGLT-1, SGLT-2 or both?

  2019cites this paper
• The protective effect of kaempferol on heart via the regulation of Nrf2, NF‐κβ, and PI3K/Akt/GSK‐3β signaling pathways in isoproterenol‐induced heart failure in diabetic rats

  2019cites this paper
• Canagliflozin review – safety and efficacy profile in patients with T2DM

  2019cites this paper
• An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions

  2019cites this paper
• Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction

  2019cites this paper
• OP-NDTJ180414 208..230

  2019cites this paper
• A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion

  2019cites this paper
• Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance

  2019cites this paper
• The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.

  2019cites this paper
• Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.

  2019cites this paper
• Cardiac troponins predict adverse clinical outcomes in stable coronary artery disease: a dose–response meta-analysis of prospective studies

  2019cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2018cites this paper
• The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments

  2018cites this paper
• Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study.

  2018cites this paper